Exchange Traded Concepts LLC Increases Holdings in Immatics N.V. (NASDAQ:IMTX)

Exchange Traded Concepts LLC grew its holdings in shares of Immatics N.V. (NASDAQ:IMTXFree Report) by 94.5% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,580 shares of the company’s stock after acquiring an additional 12,425 shares during the period. Exchange Traded Concepts LLC’s holdings in Immatics were worth $115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Bank of America Corp DE increased its stake in Immatics by 166.0% in the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after buying an additional 2,231 shares in the last quarter. Virtus ETF Advisers LLC lifted its holdings in shares of Immatics by 34.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 9,594 shares of the company’s stock valued at $68,000 after acquiring an additional 2,479 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in Immatics by 24.6% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,701 shares of the company’s stock worth $163,000 after purchasing an additional 4,477 shares during the period. Forefront Analytics LLC raised its position in Immatics by 42.3% in the 4th quarter. Forefront Analytics LLC now owns 15,911 shares of the company’s stock worth $113,000 after purchasing an additional 4,731 shares during the period. Finally, Northern Trust Corp increased its position in shares of Immatics by 31.5% during the fourth quarter. Northern Trust Corp now owns 47,226 shares of the company’s stock worth $336,000 after acquiring an additional 11,304 shares during the period. Institutional investors own 64.41% of the company’s stock.

Wall Street Analysts Forecast Growth

IMTX has been the topic of a number of research reports. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immatics in a research report on Wednesday, May 28th. They set a “buy” rating and a $10.00 target price on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immatics in a research note on Tuesday, April 1st. Finally, Wall Street Zen cut shares of Immatics from a “hold” rating to a “strong sell” rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $14.67.

Get Our Latest Report on Immatics

Immatics Stock Performance

IMTX opened at $5.44 on Wednesday. Immatics N.V. has a fifty-two week low of $3.30 and a fifty-two week high of $13.09. The company has a fifty day moving average of $5.15 and a two-hundred day moving average of $5.33. The stock has a market capitalization of $661.23 million, a price-to-earnings ratio of -32.00 and a beta of 0.83.

Immatics (NASDAQ:IMTXGet Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. The company had revenue of $20.12 million during the quarter, compared to analysts’ expectations of $14.92 million. Immatics had a negative net margin of 14.73% and a negative return on equity of 4.52%. On average, equities research analysts forecast that Immatics N.V. will post -0.72 earnings per share for the current year.

Immatics Profile

(Free Report)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Read More

Want to see what other hedge funds are holding IMTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immatics N.V. (NASDAQ:IMTXFree Report).

Institutional Ownership by Quarter for Immatics (NASDAQ:IMTX)

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.